

Table e-1. Demographic data of patients with MS and controls.

	SC	INDC	RRMS	SPMS	PPMS
Number of patients	39	11	75	49	23
Female/Male (%)	67/33	73/27	64/36	57/43	43/57
Mean age^a (years)	36	57	38	53	52
(Range)	(19-61)	(29-77)	(21-73)	(28-77)	(36-70)
Mean expanded disability status scale (Range)	NA	NA	2.4 (0-7.5)	4.8 (2.5-8)	3.3 (1-6)
Mean Disease duration, (Range)	NA	NA	6.66 (1-41)	20.6 (1-54)	7 (1-28)
Sampled during relapse/remission	NA	NA	56/19	NA	NA
Oligoclonal bands (+/-/NA)	0/28/11	2/7/2	59/15/1	37/11/1	17/5/1
Mean CSF mononuclear cells/μL (Range)	1.7 (0-6)	8.4 (0-78)	10.1 (0-90)	4.2 (0-16)	3.1 (0-12)

Abbreviations: SC = symptomatic control; INDC = inflammatory neurological disease control; RRMS = relapsing remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; PPMS = primary progressive multiple sclerosis; NA = not analyzed.

^a Age refers to patient age at sampling time point.




Figure e-1: No effect of LCN2 on oligodendrocyte progenitor cells or axonal density.

Quantification of immunochemical data from untreated myelinating cultures (28DIV) or after treatment with 10, 100 or 1000 ng/ml of LCN2 shows no significant effect on oligodendrocyte progenitor cells (A) or axonal density (B). Values plotted as mean \pm SD (n=3).